New FDA-approved hepatitis B "vaccine": could some patients stop all therapy?

According to Medical Xpress, the FDA has approved a drug described as a "vaccine" for chronic hepatitis B. The report says that in some adults this approach may allow all medication to be stopped, as long as the virus stays under control. That is rarely achieved at present. The news item does not give patient selection criteria or trial data, so those need to be checked in the FDA materials. What shall we discuss: — What do you think about fully stopping therapy in chronic HBV? Which conditions would you consider essential for doing it safely? — What should monitoring look like after discontinuation: viral load, HBsAg, how often and for how long? — How would you explain to a student the difference between long-term nucleos(t)ide analogue therapy and functional cure? For USMLE and clinical practice, this is a good occasion to review nucleos(t)ide analogues, the role of HBsAg, the concept of functional cure, and viral load monitoring. Full article: drasiiavinograd.com/blog/bepirovirsen-hibsago-hepatitis-b-usmle-review Source: Medical Xpress medicalxpress.com/news/2026-10-fda-hepatitis-shot-patients-treatment.h